Non-muscle invasive bladder cancer and bacillus Calmette-Guerin treatment

A review of the literature

Jason Alcorn, Rob L. Burton, Annie Topping

Research output: Contribution to journalArticle

Abstract

Bladder cancer is the second most common urological cancer in the UK, with over 10 000 cases diagnosed annually. With 80% of urothelial bladder cancers being non-muscle invasive, it is important to understand the treatments available. This review aims to identify and review the literature regarding bacillus Calmette-Guerin (BCG) treatment. An integrative-based review was conducted to generate a broad overview of the existing knowledge for BCG treatment. An open search of online databases was conducted to identify articles published in English from the earliest date available to September 2013, using key terms related to BCG. A significant number of articles were identified. To narrow the results and identify the most relevant articles, the search terms were cross-referenced. The resulting articles were then reviewed using the critical appraisal skills programme framework. The tools provided by CASP give a systematic, transparent and rigorous approach to the quality assessment of research studies. The research articles were then categorized under the following headings: side effects, including local, systemic and age; quality of life; and attrition. The major conclusion from this literature review is that BCG treatment, when given through an induction and maintenance regime, significantly reduces the risk of progression and recurrence. However, there are potential side effects which the patient and the nurse need to be aware. This review also highlighted that there is a lack of research from the UK and that there is a paucity of research showing why patients withdraw from BCG treatment.

Original languageEnglish
Pages (from-to)57-68
Number of pages12
JournalInternational Journal of Urological Nursing
Volume9
Issue number2
DOIs
Publication statusPublished - 1 Jul 2015

Fingerprint

Mycobacterium bovis
Urinary Bladder Neoplasms
Research
Urologic Neoplasms
Therapeutics
Nurses
Maintenance
Quality of Life
Databases
Recurrence

Cite this

@article{16bdb16da14848fdaf22fc6ec910d90a,
title = "Non-muscle invasive bladder cancer and bacillus Calmette-Guerin treatment: A review of the literature",
abstract = "Bladder cancer is the second most common urological cancer in the UK, with over 10 000 cases diagnosed annually. With 80{\%} of urothelial bladder cancers being non-muscle invasive, it is important to understand the treatments available. This review aims to identify and review the literature regarding bacillus Calmette-Guerin (BCG) treatment. An integrative-based review was conducted to generate a broad overview of the existing knowledge for BCG treatment. An open search of online databases was conducted to identify articles published in English from the earliest date available to September 2013, using key terms related to BCG. A significant number of articles were identified. To narrow the results and identify the most relevant articles, the search terms were cross-referenced. The resulting articles were then reviewed using the critical appraisal skills programme framework. The tools provided by CASP give a systematic, transparent and rigorous approach to the quality assessment of research studies. The research articles were then categorized under the following headings: side effects, including local, systemic and age; quality of life; and attrition. The major conclusion from this literature review is that BCG treatment, when given through an induction and maintenance regime, significantly reduces the risk of progression and recurrence. However, there are potential side effects which the patient and the nurse need to be aware. This review also highlighted that there is a lack of research from the UK and that there is a paucity of research showing why patients withdraw from BCG treatment.",
keywords = "Bladder cancer, Bladder installation, Cancer, Immunotherapy, Intravesical therapy, Oncology nursing",
author = "Jason Alcorn and Burton, {Rob L.} and Annie Topping",
year = "2015",
month = "7",
day = "1",
doi = "10.1111/ijun.12055",
language = "English",
volume = "9",
pages = "57--68",
journal = "International Journal of Urological Nursing",
issn = "1749-7701",
publisher = "Wiley-Blackwell",
number = "2",

}

Non-muscle invasive bladder cancer and bacillus Calmette-Guerin treatment : A review of the literature. / Alcorn, Jason; Burton, Rob L.; Topping, Annie.

In: International Journal of Urological Nursing, Vol. 9, No. 2, 01.07.2015, p. 57-68.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Non-muscle invasive bladder cancer and bacillus Calmette-Guerin treatment

T2 - A review of the literature

AU - Alcorn, Jason

AU - Burton, Rob L.

AU - Topping, Annie

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Bladder cancer is the second most common urological cancer in the UK, with over 10 000 cases diagnosed annually. With 80% of urothelial bladder cancers being non-muscle invasive, it is important to understand the treatments available. This review aims to identify and review the literature regarding bacillus Calmette-Guerin (BCG) treatment. An integrative-based review was conducted to generate a broad overview of the existing knowledge for BCG treatment. An open search of online databases was conducted to identify articles published in English from the earliest date available to September 2013, using key terms related to BCG. A significant number of articles were identified. To narrow the results and identify the most relevant articles, the search terms were cross-referenced. The resulting articles were then reviewed using the critical appraisal skills programme framework. The tools provided by CASP give a systematic, transparent and rigorous approach to the quality assessment of research studies. The research articles were then categorized under the following headings: side effects, including local, systemic and age; quality of life; and attrition. The major conclusion from this literature review is that BCG treatment, when given through an induction and maintenance regime, significantly reduces the risk of progression and recurrence. However, there are potential side effects which the patient and the nurse need to be aware. This review also highlighted that there is a lack of research from the UK and that there is a paucity of research showing why patients withdraw from BCG treatment.

AB - Bladder cancer is the second most common urological cancer in the UK, with over 10 000 cases diagnosed annually. With 80% of urothelial bladder cancers being non-muscle invasive, it is important to understand the treatments available. This review aims to identify and review the literature regarding bacillus Calmette-Guerin (BCG) treatment. An integrative-based review was conducted to generate a broad overview of the existing knowledge for BCG treatment. An open search of online databases was conducted to identify articles published in English from the earliest date available to September 2013, using key terms related to BCG. A significant number of articles were identified. To narrow the results and identify the most relevant articles, the search terms were cross-referenced. The resulting articles were then reviewed using the critical appraisal skills programme framework. The tools provided by CASP give a systematic, transparent and rigorous approach to the quality assessment of research studies. The research articles were then categorized under the following headings: side effects, including local, systemic and age; quality of life; and attrition. The major conclusion from this literature review is that BCG treatment, when given through an induction and maintenance regime, significantly reduces the risk of progression and recurrence. However, there are potential side effects which the patient and the nurse need to be aware. This review also highlighted that there is a lack of research from the UK and that there is a paucity of research showing why patients withdraw from BCG treatment.

KW - Bladder cancer

KW - Bladder installation

KW - Cancer

KW - Immunotherapy

KW - Intravesical therapy

KW - Oncology nursing

UR - http://www.scopus.com/inward/record.url?scp=84931417918&partnerID=8YFLogxK

U2 - 10.1111/ijun.12055

DO - 10.1111/ijun.12055

M3 - Article

VL - 9

SP - 57

EP - 68

JO - International Journal of Urological Nursing

JF - International Journal of Urological Nursing

SN - 1749-7701

IS - 2

ER -